RS 8359: structure given in first source; RN given refers to (+-)-isomer; RN for cpd without isomeric designation not available 6/89 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 164116 |
| SCHEMBL ID | 9369515 |
| MeSH ID | M0165722 |
| Synonym |
|---|
| 4-[(7-hydroxy-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl)amino]benzonitrile |
| 105365-76-2 |
| 4-(7-hydroxy-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-ylamino)benzonitrile |
| 119670-32-5 |
| rs 8359 |
| 4-(4-cyanoanilino)-5,6-dihydro-7-hydroxy-7h-cyclopenta[d]pyrimidine |
| 4-(4-cyanophenyl)amino-6,7-dihydro-7-hydroxy-5h-cyclopenta(d)pyrimidine |
| rs-8359 |
| benzonitrile, 4-((6,7-dihydro-7-hydroxy-5h-cyclopentapyrimidin-4-yl)amino)-, (+-)- |
| FT-0682489 |
| AKOS015856412 |
| rs-8359 [who-dd] |
| 79U9T1HIX9 , |
| 4-(4-cyanoanilino)-6,7-dihydro-7-hydroxy-5h-cyclopenta(d)pyrimidine |
| benzonitrile, 4-((6,7-dihydro-7-hydroxy-5h-cyclopentapyrimidin-4-yl)amino)- |
| FD7171 |
| 4-(7-hydroxy-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-ylamino) benzonitrile |
| SCHEMBL9369515 |
| unii-79u9t1hix9 |
| CS-6800 |
| HY-14260 |
| benzonitrile, 4-[(6,7-dihydro-7-hydroxy-5h-cyclopentapyrimidin-4-yl)amino]-;benzonitrile, 4-[(6,7-dihydro-7-hydroxy-5h-cyclopentapyrimidin-4-yl)amino]- |
| AMY15198 |
| Q27266781 |
| MS-23561 |
| DTXSID80909466 |
| benzonitrile, 4-[(6,7-dihydro-7-hydroxy-5h-cyclopentapyrimidin-4-yl)amino]- |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The results indicated that all doses were safe with no evidence of significant changes in laboratory values or cardiovascular parameters." | ( Safety, tolerability and efficacy of the reversible monoamine oxidase inhibitor RS-8359 in early clinical trials. Plenker, A; Püchler, K; Volz, HP, 1997) | 0.3 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The kinetic profile of the drug best fits a two-compartment model, and mean residence time and half-life (beta) of the drug support a twice a day regimen for extended use." | ( The pharmacokinetic profile of RS-8359. Nitanai, T; Plenker, A; Püchler, K; Sasahara, K; Witte, PU, 1997) | 0.3 |
| "The metabolic and stereoselective pharmacokinetic characteristics of seven chiral drugs with one chiral center in the hydroxy group were reviewed in vivo and in vitro including the possible chiral inversion of each drug enantiomer." | ( Stereoselective Pharmacokinetics and Chiral Inversions of Some Chiral Hydroxy Group Drugs. Bai, Q; Cai, C; Chen, F; Chen, S; Gong, P; Ma, X; Wang, D; Wang, Q; Waqas, A, 2020) | 0.56 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " No significant difference in the intestinal absorption rate was observed." | ( Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug-metabolizing enzymes. Itoh, K; Nitanai, T; Nozaki, A; Sasahara, K; Takasaki, W; Tanaka, Y; Yamamura, M, 2005) | 0.33 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " During multiple dosing twice a day for up to 6 weeks, steady state plasma drug levels were achieved within 48 h and there was no evidence of significant accumulation." | ( The pharmacokinetic profile of RS-8359. Nitanai, T; Plenker, A; Püchler, K; Sasahara, K; Witte, PU, 1997) | 0.3 |
| " Further, the [S]-enantiomer was detected in plasma of SD rats dosed with the [R]-enantiomer, suggesting [R] to [S] chiral inversion in rats." | ( Stereoselective pharmacokinetics of RS-8359, a selective and reversible inhibitor of A-type monoamine oxidase, in rats, mice, dogs, and monkeys. Hara, T; Shigehara, E; Suzuki, Y; Takasaki, W; Tanaka, Y; Tonohiro, T; Yamamura, M, 1999) | 0.3 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 13 (54.17) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (16.67%) | 5.53% |
| Reviews | 1 (4.17%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (79.17%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||